We are studying a new treatment, called Solenazumab, for Alzheimer’s disease. Solenazumab is given through intravenous injections and acts by attaching to proteins associated with the disease and preventing them from gathering in the brain. We are examining whether Solenazumab will safely and effectively slow the progression of Alzheimer’s disease, analyzing how the drug is processed by the body, and evaluating whether it will act differently across people.
Originally created: 21 May 2010 Current author: Tim Ando
Jane & Terry Semel Institute for Neuroscience & Human Behavior
760 Westwood Plaza
Los Angeles, CA 90095
UCLA Health System School of Medicine
(c) UC Regents 2011 Privacy Notice
Help Sitemap A-Z index